sponsored
PatientsVille.com Logo

PatientsVille

Humalog Medical Research Studies

Up-to-date List of Humalog Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Humalog Medical Research Studies

Rank Status Study
1 Recruiting A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes
Condition: Diabetes Mellitus Type 1
Interventions: Drug: BioChaperone insulin lispro;   Drug: Humalog®
Outcome Measures: Area under the curve (AUC);   Pharmacokinetics: Early t0.5max(Lisp);   Glucodynamics: Area under the glucose infusion rate - time curve from t=0 to 6 hours;   Glucodynamics: Early t0.5(GIRmax);   Glucodynamic: GIRmax (Maximum glucose infusion rate);   Pharmacokinetics: Area under the insulin lispro serum concentration. Time curve from t=0 to 6 hours;   Pharmacokinetics: tmax(Lisp) - Time from t=0 hours to maximum observed insulin lispro concentration;   Safety and Tolerability: adverse events, local tolerability, vital signs variation, ECG, laboratory safety parameters
2 Recruiting A Study of 2 Different Forms of Insulin Lispro in Healthy Participants
Condition: Healthy Volunteers
Intervention: Biological: Insulin Lispro
Outcome Measures: Area Under the Serum Insulin Concentration versus Time Curve From Zero to Time of Return to Baseline (AUC0-tlast) for Insulin Lispro A versus Insulin Lispro B;   Maximum Serum Insulin Concentration (Cmax) for Insulin Lispro A versus Insulin Lispro B;   Time of Maximum Observed Serum Concentration (tmax) for Insulin Lispro A versus Insulin Lispro B.;   Total Amount of Glucose Infused (Gtot) for Insulin Lispro A versus Insulin Lispro B;   Maximum Glucose Infusion Rate (Rmax) for Insulin Lispro A versus Insulin Lispro B;   Time of Maximum Glucose Infusion Rate (tRmax) for Insulin Lispro A versus Insulin Lispro B
3 Recruiting A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants
Condition: Healthy Volunteers
Interventions: Drug: LY2605541;   Drug: Insulin Lispro
Outcome Measures: Pharmacokinetics (PK): Time to Reach Peak Concentration (tmax) of LY2605541 and Insulin Lispro;   Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY2605541 and Insulin Lispro;   Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-∞) of LY2605541 and Insulin Lispro;   Maximum Glucose Infusion Rate (Rmax);   Total Glucose Infused Over Clamp Duration (Gtot)
4 Recruiting A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes
Condition: Diabetes Mellitus Type 1
Interventions: Drug: BioChaperone insulin lispro 0.2U/Kg;   Drug: BioChaperone insulin lispro 0.1U/Kg;   Drug: BioChaperone insulin lispro 0.4U/Kg;   Drug: Humalog®
Outcome Measures: Glucodynamic endpoint: Area Under the Curve GIR(0-last);   Glucodynamic endpoint: GIRMax;   Pharmacokinetic endpoint: AUC Lisp(0-last);   Pharmacokinetic endpoint: Cmax(Lisp);   Pharmacokinetics: Tmax(lisp);   Glucodynamic: TGIRmax;   Tonset of action;   Safety and Tolerability: adverse events, local tolerability, vital signs variations, ECG, laboratory safety parameters.
5 Recruiting Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes
Condition: Diabetes During Pregnancy
Interventions: Drug: NPH;   Drug: Insulin LISPRO;   Drug: Insulin glulisine
Outcome Measures: show that insulin glulisine is non-inferior to insulin lispro in a basal/bolus regimen to treat hyperglycemia in patient with gestational diabetes mellitus;   Serum blood glucose area under the curve (AUC) at one 4-hour in-clinic meal challenge;   Compare A1C at enrollment and weekly until delivery;   Compare incidence of hypoglycemic episodes <60 mg/dL with symptoms
6 Recruiting Efficacy of Insulin Lispro Mix 50/50 Therapy
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Insulin lispro mix 50/50
Outcome Measures: pre- and postprandial glucose levels in SMBG;   Total score of Questionnaire on QOL
7 Recruiting A Trial to Assess the Efficacy and Safety of BioChaperone Combo and Humalog Mix 25 in Subjects With Type 1 Diabetes
Conditions: Diabetes;   Diabetes Mellitus, Type 1
Interventions: Drug: BioChaperone® Combo;   Drug: Humalog® Mix25
Outcome Measures: End of action of 0.8 U/kg BioChaperone® Combo (time from administration until blood glucose concentration is consistently above 8.3 mmol/L during the glucose clamp procedure);   Compare pharmacodynamics and pharmacokinetics profiles between BioChaperone® Combo and Humalog® Mix25;   Number of Adverse Events
8 Recruiting The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients
Conditions: Hyperglycemia;   Diabetes Mellitus
Interventions: Drug: Active Comparator: Glargine/Lispro insulin;   Drug: Glargine/Lispro/NPH insulin arm
Outcome Measures: Average daily glucose levels in patients treated with glargine and lispro (G/L) versus glargine, lispro and NPH (G/L/N) on days 2-5 after the initiation of the treatment protocol.;   The incidence of hyperglycemia (mean daily FSG >180 mg/dL) with the two regimens.;   The incidence of hypoglycemia (FSG < 70 mg/dL) with the two regimens.
9 Not yet recruiting A Study to Compare and Measure the Effects of Insulin Peglispro and Glargine on Meal Time Insulin Requirements
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Insulin Peglispro;   Drug: Insulin Lispro;   Drug: Insulin Glargine
Outcome Measures: Pharmacodynamics: Plasma Glucose Area Under the Concentration Curve (AUC), Above Pre Meal Baseline for Insulin Lispro;   Pharmacokinetics: Area Under the Concentration Curve (AUC) for Prandial Insulin Lispro;   Pharmacodynamics: Average Glucose Infusion Rate from Euglycemic 2-step Hyperinsulinemic Clamp (M-value);   Pharmacokinetics: Area Under the Concentration Curve (AUC) for Paracetamol;   Appetite and Satiety Ratings, as Measured Using Visual Analog Scale (VAS);   Pharmacodynamics: Area Under the Concentration Curve for Triglyceride;   Pharmacokinetics: Area Under the Concentration Curve (AUC) for Insulin Lispro During Clamp
10 Unknown  PK/PD Study of Intranasal Insulin in Type I Diabetes
Condition: Type 1 Diabetes
Interventions: Drug: Insulin;   Drug: Insulin LISPRO
Outcome Measure: Insulin tolerability, PK, and PD
11 Recruiting Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery
Conditions: Type 1 Diabetes;   Type 2 Diabetes
Interventions: Drug: Regular Insulin;   Drug: Humalog
Outcome Measures: BG concentration differences at 1 and 2 hours post intervention and post operatively;   Number and percentage of target BG readings;   Episodes of hypoglycemia;   Episodes of hyperglycemia;   Total dose of insulin;   Change in glucose concentration from baseline to one, two and three hours post treatment;   Number of perioperative complications
12 Unknown  Comparison of Novo Rapid 30 Mix Injection FlexPen® and Humalog 25 Mix Injection KwikPen® in Type 2 Diabetic Patients
Conditions: Diabetes Complications;   Diabetes Mellitus, Type 2
Intervention: Device: KwikPen® and FlexPen®
Outcome Measures: HbA1c change rate from the start to 12 and 24 weeks are investigated and compared. Furthermore, using a questionnaire sheet "IDSQ-J" related to the insulin infusion device, the patient's usability and satisfaction with KwikPen® or FlexPen® are performed.;   As the secondary endpoints, the incidence of hypoglycemia, changes in body weight (BMI) and blood pressure, and the dose of insulin are investigated and compared before and after the changeover.
13 Unknown  A Study Designed to Compare 2 Formulations of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Technosphere Insulin A;   Drug: Technosphere Insulin B;   Drug: Humalog
Outcome Measures: Insulin AUC0-360min for TIB and TIA (assessment of bioequivalence) Insulin AUC0-360min for TIB to RAA (assessment of relative bioavailability);   Additional PK parameters of serum insulin and FDKP
14 Recruiting Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Drug: Sitagliptin + glargine;   Drug: Basal Bolus;   Drug: Metformin and sitagliptin;   Drug: Metformin and sitagliptin + glargine 50%;   Drug: Metformin and sitagliptin + glargine 80%
Outcome Measures: Glycemic control;   Hypoglycemia;   Hyperglycemia;   Total daily insulin dose;   Days of hospitalization;   ICU need;   Composite of hospital complications;   Acute Renal Failure;   Hospital mortality
15 Not yet recruiting Cystic Fibrosis (CF) Exacerbation and Insulin Treatment
Conditions: Cystic Fibrosis;   Impaired Glucose Tolerance;   Pulmonary Exacerbation
Interventions: Drug: novorapid / Humalog short acting insulin;   Drug: Novo Rapid Insulin (Novonordisk)
Outcome Measures: delta Forced Expiratory Volume in 1 second (FEV1%) predicted;   change in Body Mass Index (BMI)
16 Not yet recruiting Linagliptin Inpatient Trial
Condition: Type 2 Diabetes
Interventions: Drug: Linagliptin;   Drug: Basal Bolus;   Drug: Linagliptin + glargine 50%;   Drug: Linagliptin + 80% Glargine
Outcome Measures: Differences in glycemic control;   hypoglycemic events;   episodes of hyperglycemia;   daily dose of insulin;   Length of hospital stay;   ICU Care;   Hospital complications;   Acute renal failure;   Hospital mortality;   Fasting and postprandial BG concentration;   HbA1c;   emergency room visits;   Number of complications;   Linagliptin after discharge
17 Recruiting Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: insulin lispro injection, exenatide injection;   Drug: insulin lispro injection
Outcome Measures: the glycemic remission rate in different groups;   the improvement of β-cell function in different groups.;   the time of glycemic remission in different groups
18 Recruiting A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
Conditions: Type 2 Diabetes;   Chronic Kidney Disease
Interventions: Drug: Dulaglutide;   Drug: Insulin glargine;   Drug: Insulin lispro
Outcome Measures: Change from Baseline in Hemoglobin A1c (HbA1c) at 26 Weeks;   Change from Baseline in HbA1c at 52 Weeks;   Percentage of Participants whose HbA1c is <7.0% at 26 Weeks and 52 Weeks;   Percentage of Participants whose HbA1c is <8.0% at 26 Weeks and 52 Weeks;   Change from Baseline in 8-Point Self-Monitored Plasma Glucose (SMPG) at 26 Weeks and 52 Weeks;   Change from Baseline in Fasting Glucose at 26 Weeks and 52 Weeks;   Mean Daily Insulin Lispro Use at 26 Weeks and 52 Weeks;   Percentage of Participants with estimated average glucose <154 mg/dL at 26 Weeks and 52 Weeks;   Change from Baseline in Serum Creatinine (SCr) at 26 Weeks and 52 Weeks;   Change from Baseline in estimated Glomerular Filtration Rate (eGFR) at 26 Weeks and 52 Weeks;   Change from Baseline in estimated Creatinine Clearance (eCrCl) at 26 Weeks and 52 Weeks;   Change from Baseline in Urinary Albumin to Creatinine Ratio (UACR) at 26 Weeks and 52 Weeks;   Change from Baseline in Body Weight at 26 Weeks and 52 Weeks;   Percentage of Participants with Hypoglycemic Episodes;   Hypoglycemic Episode Rate;   Percentage of Participants with Allergic/Hypersensitivity Reactions
19 Not yet recruiting Exenatide for Stress Hyperglycemia
Condition: Stress Hyperglycemia
Interventions: Drug: Exenatide;   Drug: Insulin
Outcome Measures: Percentage of patients spending more than 50 % of the time in the glycemic target range (100 to 140 mg/dl);   Hypoglycemia;   Severe hypoglycemia;   Number of patients needing rescue to insulin therapy protocol;   Number of adverse events occuring in the exenatide group;   Mortality;   Postoperative morbidity;   The mean (GluAve) and standard deviation (GluSD) of blood glucose;   The coefficient of variability (GluCV) of blood glucose level;   Mean number of blood glucose measured;   Mean difference between each blood glucose measurement and 120 mg/dl;   Perioperative cardiac mortality;   Perioperative non cardiac mortality;   Length of stay in intensive care unit
20 Unknown  Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Insulin (IN-105) in Type 1 Diabetes Patients
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: IN-105;   Drug: Insulin Lispro Injection
Outcome Measures: AUC (Insulin and Blood Glucose);   Frequency of Adverse Events

These studies may lead to new treatments and are adding insight into Humalog etiology and treatment.

A major focus of Humalog research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Humalog